{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:30:45Z","timestamp":1771997445099,"version":"3.50.1"},"reference-count":42,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Not all melanomas are the same. They differ in presentation, mutational status, and behavior. Desmoplastic melanoma (DM) is a rare subtype of melanoma which carries a high tumor mutation burden and is found in highly sun-exposed areas. Although many cutaneous melanomas are pigmented, DM is amelanotic and frequently mistaken for more benign lesions. It is composed of spindle cells surrounded by a dense fibrinous matrix. It frequently carries NF1 mutations. It is exquisitely sensitive to single-agent PD1 blockade resulting in deep, rapid responses at all stages. These responses with single-agent pembrolizumab are durable with a 96% 3-year melanoma specific survival rate. This has influenced recommended treatments for unresectable and resectable disease. Single-agent PD1 blockade is recommended first line for unresectable disease with a reported overall response rate of 89%. The first prospective neoadjuvant study in DM demonstrated a pathologic complete response of 57% after three cycles of pembrolizumab, suggesting potential benefit to the use of neoadjuvant therapy in resectable disease. Owing to the low incidence of sentinel lymph node positivity and lack of correlation with overall survival, sentinel lymph node biopsy can be eliminated in patients with pure DM. Adjuvant radiation has been shown to result in improved local control in cases of high-risk DM, but studies have not demonstrated an impact on distant metastasis-free survival. For DM, less is more.<\/jats:p>","DOI":"10.1200\/edbk-25-472752","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:59:35Z","timestamp":1749758375000},"source":"Crossref","is-referenced-by-count":2,"title":["Management of Cutaneous Melanoma, With a Special Focus on Desmoplastic Melanoma"],"prefix":"10.1200","volume":"45","author":[{"given":"Kari L.","family":"Kendra","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M.","family":"Contreras","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire F.","family":"Verschraegen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Hasanov","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01125"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.009"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200239"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Lucas MW Lijnsvelt J Saskia PS et al: The NADINA trial: A multicenter randomised phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. Oral Presentation ASCO Annual Meeting 2022 Chicago IL","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.066"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25317"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000155071.86944.a6"},{"key":"e_1_3_3_17_2","first-page":"e4931","article-title":"Desmoplastic melanoma: Clinical characteristics and survival in the US population","volume":"11","author":"Huayllani MT","year":"2019","unstructured":"Huayllani MT, Sisti A, Restrepo DJ, et al: Desmoplastic melanoma: Clinical characteristics and survival in the US population. Cureus 11:e4931, 2019","journal-title":"Cureus"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2011.01704.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2024.09.005"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26677"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25148"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12654"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119716"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.03.022"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004038"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.03.010"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.007"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3382"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25187"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","unstructured":"Kendra KL Bellasea S Eroglu Z et al. Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma. Plenary presentation at AACR Annual Meeting 2023; FL","DOI":"10.1158\/1538-7445.AM2023-CT009"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","unstructured":"Kendra KL Bellasea SL Eroglu Z et al. Abstract PR006: High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512. Oral presentation at AACR IO; February 2025; LosAngeles CA","DOI":"10.1158\/2326-6074.IO2025-PR006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17154"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0036"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21635"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2022.12.347"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12597"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9502"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05368-8"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10263"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-472752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:59:36Z","timestamp":1749758376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-472752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-472752"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-472752","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e472752"}}